Viridian Therapeutics, Inc.\DE (VRDN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 25M 50M 75M Q3 '24: 86K Q4 '24: 72K Q1 '25: 72K Q2 '25: 75K Q3 '25: 70.6M Q4 '25: 132K Q1 '26: 141K Q2 '26: 284K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

-600K 0 600K 1.2M 1.8M Q1 '15: 557K Q2 '15: 779K Q3 '15: 758K Q4 '15: 1.2M Q1 '16: 1.4M Q2 '16: 1.5M Q3 '16: 337K Q4 '16: -183K Q1 '15 Q2 '15 Q3 '15 Q4 '15 Q1 '16 Q2 '16 Q3 '16 Q4 '16

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '24: -83.5M Q4 '24: -87.5M Q1 '25: -93.9M Q2 '25: -106.8M Q3 '25: -40M Q4 '25: -122.7M Q1 '26: -116.2M Q2 '26: -126.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '24: -76.7M Q4 '24: -79.7M Q1 '25: -86.9M Q2 '25: -100.7M Q3 '25: -34.6M Q4 '25: -120.4M Q1 '26: -104.9M Q2 '26: -127.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 300K 600K 900K Q1 '15: 760K Q2 '15: 678K Q3 '15: 577K Q4 '15: 456K Q1 '16: 629K Q2 '16: 628K Q3 '16: 599K Q4 '16: 692K Q1 '15 Q2 '15 Q3 '15 Q4 '15 Q1 '16 Q2 '16 Q3 '16 Q4 '16

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '24: -67.7M Q4 '24: -73.3M Q1 '25: -92.7M Q2 '25: -75.4M Q3 '25: -84.6M Q4 '25: -23.8M Q1 '26: -119.7M Q2 '26: -105.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '24: -68M Q4 '24: -73.4M Q1 '25: -92.7M Q2 '25: -75.4M Q3 '25: -84.7M Q4 '25: -24M Q1 '26: -119.7M Q2 '26: -106.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q1 '23: 42.2M Q2 '23: 43.3M Q3 '23: 43.7M Q1 '24: 61.1M Q2 '24: 63.9M Q3 '24: 66.4M Q1 '25: 81.3M Q2 '25: 81.6M Q1 '23 Q2 '23 Q3 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '22: -4.07 Q1 '23: -4.70 Q2 '23: -4.91 Q3 '23: -5.14 Q4 '23: -5.31 Q1 '24: -4.49 Q2 '24: -4.24 Q3 '24: -4.30 Q4 '22 Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.